Tomorrow Morning (NYSE American: SER) Tops Our Watchlist — A Parkinson's Biotech With Fewer Than 12M Shares in the Float

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Serina Therapeutics, Inc. (NYSE American: SER) Just Landed On Our Watchlist For Tomorrow Morning —Wednesday, September 9, 2026… Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Consider Starting Your Own Research On (SER) Tonight… September 8, 2026 Dear Reader, When the global Parkinson's therapeutics sector is projected to grow from $8.38B in 2026 to more than $15B by 2034 — a compound annual growth rate near 8.2%, according to Fortune Business Insights — the names worth watching aren't necessarily the large-cap pharma companies that everyone already follows… They're the ones building something fundamentally different at the platform level. North America alone accounts for more than a third of the global Parkinson's therapeutics market, and the need for better-tolerated, longer-acting formulations has never been more clear… Serina Therapeutics, Inc. (NYSE American: SER) is one of those names. This Huntsville, Alabama-based clinical-stage biotechnology company has developed a proprietary polymer technology — the POZ Platform™ — designed to transform existing therapeutic compounds into optimized formulations that work longer, release more smoothly, and reduce the side-effect burden that often limits current treatments for neurological conditions. The company's lead candidate, SER-252, is a POZ-conjugated apomorphine now advancing through a Phase 1b registrational trial in patients with advanced Parkinson's disease… And the pace of execution around this company right now suggests the timeline could be accelerating. Serina Therapeutics, Inc. (NYSE American: SER) will be topping our watchlist tomorrow morning—September 9, 2026. But keep in mind, (NYSE American: SER) has a float less than 12M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. And according to analyst consensus data, two analysts currently cover (SER) with bullish ratings. Thomas Shrader at BTIG holds a target of $8, while Justin Walsh at Jones carries a target of $11 — putting the average consensus at $9.50, which suggests more than 250% upside potential from the company's recent $2.70 range. What Makes the POZ Platform Different At its core, the POZ Platform™ is built on poly(2-oxazoline), a synthetic, water-soluble polymer engineered to give researchers greater control over how attached therapeutic agents are loaded and released into the body. The concept is straightforward but powerful… Many approved compounds that treat Parkinson's disease are effective but limited. Short half-lives force patients into dosing schedules that create peaks and valleys in the bloodstream. Narrow therapeutic windows mean too much of a compound causes toxicity, while too little leaves symptoms uncontrolled. And inconsistent blood levels contribute to the motor fluctuations and dyskinesia that make daily life so difficult for patients with advanced Parkinson's… Serina Therapeutics, Inc. (NYSE American: SER) is addressing those limitations head-on by conjugating proven active ingredients to its POZ polymer, creating formulations designed to maintain stable, sustained levels through subcutaneous delivery. The company's lead program, SER-252, is specifically designed to provide continuous dopaminergic stimulation — an approach shown to reduce the severity of levodopa-related motor complications in patients with advanced Parkinson's disease. Perhaps just as importantly, preclinical work supports the potential of SER-252 to deliver that stimulation without the skin reactions that have historically limited older infusion-based therapies. That distinction matters more than it might appear on the surface. Skin-site tolerability has been a persistent challenge for subcutaneous delivery systems in neurology. A compound that can provide continuous dopamine receptor activation without that barrier could represent a meaningful step forward for patients who have exhausted satisfactory oral options… And with Parkinson's patient numbers projected to rise substantially over the coming decade as populations age, the addressable market for a genuinely differentiated therapy in this space only grows from here. The platform's versatility extends well beyond a single compound. Serina has a second candidate, SER-214, a POZ-conjugated rotigotine targeting early Parkinson's and Restless Leg Syndrome, which has already completed a Phase 1a clinical evaluation. And the company holds a non-exclusive license agreement with Pfizer to use its POZ polymer technology in lipid nanoparticle delivery formulations — a validation of the platform's broader applicability across modalities including RNA-based therapeutics and antibody-based conjugates. That kind of large-pharma partnership around a delivery technology, even in a non-exclusive capacity, speaks to the underlying quality of what the POZ Platform™ can do… A Rapid-Fire Stretch of Milestones The past several months have been unusually dense with forward progress for (SER). In July 2026, the company completed enrollment and dosing of all eight patients in Cohort 1 of its Phase 1b registrational trial for SER-252 — ahead of the company's previously disclosed end-of-third-quarter guidance. That acceleration matters. In clinical-stage biotech, delivering milestones ahead of schedule signals operational discipline, strong site performance, and genuine demand from clinical researchers and patients willing to participate in the study… CEO Steve Ledger described the moment in direct terms: "The progression from sentinel group review to completion of dosing reflects strong execution by our clinical sites and study team," he stated in a July 2026 announcement. Top-line data from the single-ascending-dose arm of the registrational study is now targeted for the first half of 2027 — a near-term readout that could refocus attention on (SER) in a meaningful way. The trial itself is designed as a randomized, double-blind, placebo-controlled Phase 1b study with both single-ascending-dose and multiple-ascending-dose components, conducted across sites in the United States and Australia, with plans to expand to South Korea and Taiwan. Meanwhile, the company has been building out the infrastructure around its lead candidate. In June 2026, Serina Therapeutics, Inc. (NYSE American: SER) entered a development partnership with Gannet BioChem, a specialty CDMO with more than 30 years of expertise in activated polymers and complex therapeutic programs, to support process development, scale-up, and manufacturing for SER-252. Gannet BioChem's CEO called the partnership a fit, citing Serina's position at a stage where experienced manufacturing support becomes essential for continued progress. That same announcement confirmed that SER-252 had received FDA clearance of its Investigational New Compound application, enabling further advancement into clinical development… Then in July, Serina Therapeutics, Inc. (NYSE American: SER) appointed Farrell Simon, Pharm.D., to its Board of Directors. Simon currently serves as Chief Commercial Officer at Trevi Therapeutics, where he helped support financings totaling more than $400M from top-tier firms including Frazier, Vivo, Venrock, and Viking. Prior to Trevi, he spent a decade at Pfizer in senior commercial and strategic leadership roles. His background in commercial readiness, business development, and capital markets engagement adds a dimension that could become increasingly relevant as SER-252 progresses through later-stage development… The company ended Q2 2026 with $23M in cash and cash equivalents, providing a financial foundation to advance SER-252 through its ongoing clinical milestones. 9 Reasons Why We’ll Have All Eyes On (SER) Tomorrow Morning—Wednesday, September 9, 2026… 1. Small Float: with fewer than 12M shares listed as available to the public, SER’s small float could have the potential for big moves if demand begins to shift. 2. Analyst Targets: with BTIG carrying an $8 target and Jones with an $11 target, SER currently has two bullish analyst ratings with a $9.50 average across those published estimates. 3. Phase 1b: the lead candidate at SER, SER-252, is advancing through a randomized, double-blind, placebo-controlled Phase 1b registrational trial in advanced Parkinson's disease. 4. Early Execution: after completing enrollment and dosing for all eight Cohort 1 patients ahead of its previously disclosed end-of-Q3 guidance, SER has already delivered one key clinical milestone ahead of schedule. 5. 2027 Readout: top-line data from the single-ascending-dose portion of the SER-252 study are targeted for H1 2027, giving SER a defined future clinical milestone to follow. 6. POZ Platform: the proprietary poly(2-oxazoline) technology behind SER is designed to provide greater control over therapeutic loading and release through polymer conjugation. 7. Pfizer License: through a non-exclusive agreement with Pfizer covering potential use of POZ technology in lipid nanoparticle formulations, SER has established a relationship with one of the world's largest pharmaceutical companies. 8. Manufacturing Support: a June 2026 development partnership with Gannet BioChem gives SER specialized support for SER-252 process development, scale-up, and manufacturing. 9. Cash Position: after ending Q2 2026 with approximately $23M in cash and cash equivalents, SER reported financial resources available to support its ongoing clinical work. Pull Up (SER) Before Tomorrow Morning… Serina Therapeutics, Inc. (NYSE American: SER) sits at the intersection of a massive and accelerating therapeutic market, a differentiated delivery platform, and a clinical timeline that just moved forward… The Parkinson's therapeutics sector continues to expand as the global population ages and demand for more tolerable, longer-acting treatments intensifies. This company — with a sub-12M share float, $23M in cash, a lead program hitting milestones ahead of schedule, a CDMO partnership securing its manufacturing path, new board-level commercial expertise, and analyst targets suggesting significant upside from current levels — could be a name that deserves a closer look. The pieces are assembling around a clinical-stage biotech that appears to be executing on every front that matters at this stage of development. And with a data readout from the single-ascending-dose arm coming in the first half of 2027, the next several months could be decisive for where it goes from here… We will have all eyes on (SER) tomorrow morning. Consider taking a look at (SER) tonight. Also, keep an eye out for my next update, it could be coming earlier than usual. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and LFG Equities Corp., TD Media LLC has been hired for a period beginning on 09/08/2026 and ending on 09/09/2026 to publicly disseminate information about (SER:US) via digital communications. Under this agreement, LFG Equities Corp. has paid TD Media LLC fifty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid one hundred forty seven thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (SER:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/ser-E8Asv/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe About our service provider Sent by jeff@stocknewstrends.com

Analyst Targets And Triggered Technicals Pin (Nasdaq: VERU) To Our Radar (Low Float)

A conference invitation is usually filler. This one is a marker.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Analyst Targets And Triggered Technicals Pin (Nasdaq: VERU) To Our Radar (Low Float) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* September 8th Greetings, Friend! A conference invitation is usually filler. This one is a marker. Veru Inc. (Nasdaq: VERU) said last week that Chairman, President and Chief Executive Officer Mitchell Steiner, M.D., will hold a fireside chat at the 2026 Cantor Global Healt-hcare Conference on September 9th, his first scheduled appearance since a summer in which the company closed a study, cleared a patent and lined up supply with the largest name in wei-ght management. Start with the patent, because it reframes everything else. In early August the U.S. Patent and Trademark Office issued a notice of allowance on method of use claims covering enobosarm given with wei-ght lo-ss medicines, running to at least October 3rd, 2044. The claims are not narrow. They cover concurrent dosing with semaglutide, addition to an existing regimen, and continuation after semaglutide is stopped. A pending application on an oral modified release formulation could carry protection into 2046. Stated protection runway for the enobosarm combination estate. Source: Veru Inc. news release of August 4th, 2026. Underneath the filing sits evidence already generated. The completed Phase 2b QUALITY study enrolled 168 patients aged 60 and older receiving semaglutide. Enobosarm at 3 mg produced a 100% relative reduction in lean mass loss versus placebo at a p value below 0.001, and the 6 mg arm showed 42% greater relative fat mass loss at 16 weeks. On the measure that translates to daily life, the 3 mg arm cut the share of subjects losing at least 10% of stair climb power by 59.8%. Measured results versus placebo in the Phase 2b QUALITY study. Source: Veru Inc. cardiometabolic program disclosures. The confirmatory work is underway and fully staffed. PLATEAU closed enrollment at 239 patients, ahead of its roughly 200 patient target. It is double blind and placebo controlled, running 68 weeks in patients aged 65 and older with a body mass index of 35 or greater who are starting semaglutide. Interim data at 32 weeks is guided to early 2027, topline to the fourth quarter. The company also strengthened its footing over the same period. Cash and restricted cash reached $23.9Mn at June 30th against $15.8Mn at the close of fiscal 2025, with total stockholders' equity of $28.4Mn, and Chief Financial Officer Michele Greco said on the call that the balance is expected to fund operations beyond the interim analysis. About Veru Inc. (Nasdaq: VERU) Veru Inc. is a late clinical stage biopharmaceutical company based in Miami, FL, focused on cardiometabolic and inflammatory disease. Enobosarm, the lead asset, is an oral selective androgen receptor modulator evaluated in six clinical trials across more than 1,100 patients, with consistent gains in lean mass and improved physical function. The second molecule, sabizabulin, targets chronic inflammation related to atherosclerotic cardiovascular disease and depends on additional funding. Value accrues through clinical milestones, patent claims and partnering. The Company reached this structure through divestiture rather than acquisition. Veru sold its FC2 consumer health business for $18Mn at the end of December 2024, netting roughly $12.5Mn, retiring a $9.9Mn royalty liability and reducing headcount from about 210 to 22. CEO Mitchell Steiner called it the step that let Veru operate as a pure biopharmaceutical company. Sector Analysis: Where This Theme Sits The category is large and still growing, but second order questions are where the next differentiation comes from. Morgan Stanley Research put its 2035 base case at $190Bn against $79Bn in 2025, with United States adoption rising toward roughly 30% of the obese and diabetic population. Goldman Sachs Research projected the category could approach $120Bn by 2035.  Veru cites obesity prevalence of 41.5% among the 47.4Mn people in Medicare Part D plans, and notes current therapies reach less than 2% of eligible patients. The Third Quarter Call Management's framing on the August call was structural rather than promotional. Chief Executive Officer Mitchell Steiner returned repeatedly to one figure, that 62.6% of patients still had clinical obesity when they reached the one year plateau, and argued older patients are most exposed to falling below a critical muscle threshold. He flagged that Medicare coverage of G-L-P-1 therapies began on July 1st, 2026, and confirmed that Novo Nordisk supplies Wegovy for the study at no charge in return for a right of first negotiation on combination rights. There Are 7 Key Potential Catalysts Putting (Nasdaq: VERU) On Our Radar #1. Allowed Claims Extend Almost Two Decades Past Today. The method of use claims run to at least October 3rd, 2044, turning the VERU asset from a study result into a defensible commercial position. #2. A Fully Enrolled Study With A Scheduled Interim Look. PLATEAU finished enrollment at 239 patients and the 32 week interim analysis for VERU is guided to early 2027. #3. A Float Under 16Mn Shares May Create Potential For Heightened Volatility. With approx. 15.48Mn shares in its float, VERU screens as a low float idea, meaning the potential for heightened volatility may be significant. #4. Technical Indicators Are Flashing Bullish Signals Across Terms. Barchart.com's Opinion page reported 12 of 13 technical indicators it tracks to be triggered at close on Friday. This includes the website’s composite “Trend Seeker” indicator. #5. Reimbursement Policy Moved Toward The Target Cohort. Medicare coverage of G-L-P-1 therapies began on July 1st, 2026, addressing the payer question that has long sat over the exact population VERU is studying. #6. VERU Has 2 Analyst Targets Pointing To Significant Upside Potential. An analyst target ($25) from Canaccord Genuity and a target ($24) from Oppenheimer hint at VERU potentially being undervalued from current chart levels. #7. Novo Nordisk Holds A Right Of First Negotiation. The Danish firm supplies Wegovy at no cost and holds first negotiation rights on combination use, so any partnering discussion involving VERU has a known starting point. In Summary What makes this name worth understanding is not one number, it is the shape of the setup. A category growing toward triple-digit scale carries a well documented side effect, and one small company has spent years building evidence and patent claims around solving it. The 16 week evidence is on the record. The 68 week test is fully enrolled with a dated readout. Protection runs deep into the 2040s. Against that sit the constraints of a pre commercial company with one lead asset. For anyone building a watchlist around the muscle preservation theme, start here. Now official: coverage is officially initiated on Veru Inc. (Nasdaq: VERU). Stay on the lookout for updates heading your way shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice

Duolingo’s sharp rebound and resilient user engagement suggest AI may be an ally—not an existential threat. But with monetization challenges and valuation concerns still looming, can it truly follow Netflix’s comeback script?  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Read online Is Duolingo the Next Netflix-Style Comeback Story? Duolingo’s sharp rebound and resilient user engagement suggest AI may be an ally—not an existential threat. But with monetization challenges and valuation concerns still looming, can it truly follow Netflix’s comeback script? 100% overnight gains? (From The Oxford Club) Key Points Evercore analyst Mark Mahaney upgraded Duolingo to Outperform with a $210 price target, arguing fears of ChatGPT replacing the app were overstated. Duolingo's engagement metrics remain strong, with daily active users at an all-time high, retention above 80%, and lapsed users returning through recent campaigns. Bears still cite risks including slow conversion of users into paying subscribers, China regulatory hurdles, and questions about how much upside remains after the stock's rebound. Special Report: Move Your Money Here Before September 30th (From TradeSmith)   When the AI boom took hold, few companies looked more vulnerable than Duolingo Inc. (NASDAQ: DUOL). If a chatbot could teach you a language for free, so the thinking went, why bother with a dedicated app at all? That fear sent the stock down more than 80% in less than a year, but since bottoming out last April, shares of the language-learning app have been rallying hard. With the stock having gained about 70% through the end of last week, this week’s jump came thanks to a fresh analyst upgrade. Evercore’s Mark Mahaney has turned bullish, saying the threat from ChatGPT and its peers has been wildly overstated. Alongside a fresh Outperform rating, he raised his price target to $210, indicating more than 30% upside from current levels. Maheney also reached for an interesting comparison. He likened Duolingo's setup to that of Netflix Inc. (NASDAQ: NFLX) in 2022, when the streaming giant's shares fell more than 75% before a wave of product improvements powered a spectacular recovery. As we head into the final few months of 2026, could Duolingo be setting up for a Netflix-style comeback of its own? Anthropic's Revenue Surged 80X Ahead of Its IPO Filing (Ad) Anthropic is now valued at over $1 trillion, more than every U.S. airline combined and larger than the U.S. defense budget. Its annualized revenue grew 80x in the first quarter, and an IPO could arrive as early as October. For a limited time, investors can access a report detailing how to explore a pre-IPO stake in Anthropic for $29, a 94% discount off the retail price. The package includes a year of Disruptors and Dominators, monthly stock ideas, and four special reports. Claim the discounted Anthropic pre-IPO report before Monday night's deadline. Why the AI Fear Was Overdone The heart of the bullish case is that the market has fundamentally misjudged the AI threat. Rather than stealing Duolingo's users, tools like ChatGPT appear to coexist with the app, and often the same people use both. The evidence is telling. Evercore's research found that most language learners who use ChatGPT also use Duolingo, and crucially, they use the app just as intensively as Duolingo's most dedicated fans. Far from cannibalizing the business, the AI-chatbot crowd treats ChatGPT as a casual supplement, reaching for it mostly for light, travel-related dabbling rather than serious study. Given Duolingo’s stock had more than 80% of its value wiped out on the assumption that this wouldn’t be the case, that distinction matters enormously. It suggests the company’s committed, habit-forming core, the users who log in day after day to keep their streaks alive, remains firmly intact. But with shares still down 70% from last year’s all-time high, it feels like the market still hasn’t quite priced this in yet. A Business in Good Health Beyond the AI question, the underlying numbers paint a picture of a company in good health. User growth, for example, has been accelerating rather than fading, with daily active users recently hitting an all-time high. Just as important, those users are sticking around, with retention rates well above 80%. They’re also coming back, with a clever one-off campaign to win back lapsed learners bringing millions flooding back to the app. That’s not exactly the kind of engagement momentum you’d expect from a product being disrupted by AI. Duolingo is also widening its appeal well beyond languages, pushing into subjects like math, music, and even chess, while using AI to slash the cost of premium features. One of the app's tools saw its cost per use collapse from around 30 cents to less than 1 cent, a neat illustration that, far from being replaced by AI, Duolingo is making it work in its favor. Trump’s Dollar Reset (Ad) Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December. Watch Porter Stansberry's full briefing and get his three steps to prepare before December. Where the Bears Still See Risk For all the renewed enthusiasm, the skeptics have not been entirely silenced, and their concerns deserve a fair hearing. The most pressing is the gap between Duolingo's booming user numbers and the slower pace at which it converts those users into paying subscribers. Strong engagement is one thing; turning it into hard revenue is quite another. Then there are external risks, from the ever-present threat of new and more capable AI rivals to the regulatory complications of operating in China. This market holds the key to much of Duolingo’s planned growth. In addition, with such a sharp rebound in shares already, investors are right to question whether most of the easy gains have already been made. Could History Repeat? So, could Duolingo really deliver the next Netflix-style comeback? The parallel is appealing: a beaten-down favorite, written off too soon, staging a comeback on the back of relentless product innovation. If the comparison holds, today's price could look cheap in hindsight, just as Netflix's did after its own 700% recovery. Yet caution is warranted. Netflix operated at a vastly greater scale, and the monetization questions hanging over Duolingo are real and unresolved. History, as ever, rarely repeats itself so cleanly, and a single upbeat analyst call doesn’t guarantee a repeat performance. Still, the direction of travel is hard to ignore. Duolingo seems to have answered its biggest existential question, with strong evidence that AI is proving more friend than foe, and its engagement numbers keep climbing. For investors willing to look past the near-term doubts, this recovering favorite may be at the start of a triple-digit rally of its own. Read this article online › Recommended Stories AI Token Costs Are Changing the Hardware vs. Software Debate The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) 3 ETFs That Could Move as Rate Expectations Shift Why Trump really wants Greenland (From Porter & Company) 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie's Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains Why Hewlett Packard Enterprise’s Sell-Off May Not Last     Stay Ahead of the Market The best investment opportunities don't wait. Get our research and stock ideas delivered straight to your smartphone—so you never miss a market-moving opportunity. Our text alerts ensure you see timely stock ideas and professional research reports instantly, whether you're in a meeting, commuting, or away from your desk. Get Text Alerts from American Market News (free)     Update your email preferences or unsubscribe here © 2026 American Market News | MarketBeat Media, LLC 345 N Reid Place #620 Sioux Falls, SD 57103, United States